1 April 2024 false No description of principal activity Taxfiler 2024.6 13953332business:PrivateLimitedCompanyLtd2024-04-012025-03-31 139533322024-03-31 139533322024-04-012025-03-31 13953332business:AuditExemptWithAccountantsReport2024-04-012025-03-31 13953332business:FilletedAccounts2024-04-012025-03-31 139533322025-03-31 13953332business:Director12024-04-012025-03-31 13953332business:RegisteredOffice2024-04-012025-03-31 139533322024-03-31 13953332core:WithinOneYear2025-03-31 13953332core:WithinOneYear2024-03-31 13953332core:ShareCapitalcore:PreviouslyStatedAmount2025-03-31 13953332core:ShareCapitalcore:PreviouslyStatedAmount2024-03-31 13953332core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2025-03-31 13953332core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-03-31 13953332core:PreviouslyStatedAmount2025-03-31 13953332core:PreviouslyStatedAmount2024-03-31 13953332business:SmallEntities2024-04-012025-03-31 13953332countries:EnglandWales2024-04-012025-03-31 13953332core:MotorVehicles2024-04-012025-03-31 13953332core:ComputerEquipment2024-04-012025-03-31 13953332core:MotorVehicles2024-03-31 13953332core:ComputerEquipment2024-03-31 13953332core:MotorVehicles2025-03-31 13953332core:ComputerEquipment2025-03-31 13953332business:OrdinaryShareClass12024-04-012025-03-31 13953332business:OrdinaryShareClass12023-04-012024-03-31 139533322023-04-012024-03-31 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. 13953332 (England and Wales)
Revisepharma Ltd Unaudited accounts for the year ended 31 March 2025
Revisepharma Ltd Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Revisepharma Ltd Company Information for the year ended 31 March 2025
Director
Zhyar Said
Company Number
13953332 (England and Wales)
Registered Office
41 Oldfields Road Sutton Surrey SM1 2NB England
Accountants
Blythe & Co 41 Oldfields Road Sutton Surrey SM1 2NB
- 3 -
Revisepharma Ltd Statement of financial position as at 31 March 2025
2025 
2024 
Notes
£ 
£ 
Fixed assets
Tangible assets
4
44,737 
- 
Current assets
Cash at bank and in hand
81,721 
80,364 
Creditors: amounts falling due within one year
5
(22,372)
(19,493)
Net current assets
59,349 
60,871 
Net assets
104,086 
60,871 
Capital and reserves
Called up share capital
6
1 
1 
Profit and loss account
104,085 
60,870 
Shareholders' funds
104,086 
60,871 
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 11 April 2025 and were signed on its behalf by
Zhyar Said Director Company Registration No. 13953332
- 4 -
Revisepharma Ltd Notes to the Accounts for the year ended 31 March 2025
1
Statutory information
Revisepharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 13953332. The registered office is 41 Oldfields Road, Sutton, Surrey, SM1 2NB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Motor vehicles
25% Straight Line
Computer equipment
25% Straight Line
4
Tangible fixed assets
Motor vehicles 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 April 2024
- 
- 
- 
Additions
45,881 
819 
46,700 
At 31 March 2025
45,881 
819 
46,700 
Depreciation
Charge for the year
1,912 
51 
1,963 
At 31 March 2025
1,912 
51 
1,963 
Net book value
At 31 March 2025
43,969 
768 
44,737 
- 5 -
Revisepharma Ltd Notes to the Accounts for the year ended 31 March 2025
5
Creditors: amounts falling due within one year
2025 
2024 
£ 
£ 
VAT
10,833 
- 
Taxes and social security
10,320 
7,716 
Other creditors
187 
- 
Loans from directors
- 
10,745 
Accruals
1,032 
1,032 
22,372 
19,493 
6
Share capital
2025 
2024 
£ 
£ 
Allotted, called up and fully paid:
100 Ordinary Shares of £0.01 each
1 
1 
7
Average number of employees
During the year the average number of employees was 0 (2024: 0).
- 6 -